Limits...
Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Kanda T, Nakamoto S, Wu S, Nakamura M, Jiang X, Haga Y, Sasaki R, Yokosuka O - J Clin Transl Hepatol (2015)

Bottom Line: There are two forms of antiviral agents against HAV: direct-acting antivirals (DAAs) and host-targeting agents (HTAs).Among the HTAs, amantadine and interferon-lambda 1 (IL-29) inhibit HAV IRES-mediated translation and HAV replication.Janus kinase (JAK) inhibitors inhibit La protein expression, HAV IRES activity, and HAV replication.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Inohana, Chuo-ku, Chiba, Japan.

ABSTRACT
Hepatitis A virus (HAV) infection is a major cause of acute hepatitis and occasionally leads to acute liver failure in both developing and developed countries. Although effective vaccines for HAV are available, the development of new antivirals against HAV may be important for the control of HAV infection in developed countries where no universal vaccination program against HAV exists, such as Japan. There are two forms of antiviral agents against HAV: direct-acting antivirals (DAAs) and host-targeting agents (HTAs). Studies using small interfering ribonucleic acid (siRNA) have suggested that the HAV internal ribosomal entry site (IRES) is an attractive target for the control of HAV replication and infection. Among the HTAs, amantadine and interferon-lambda 1 (IL-29) inhibit HAV IRES-mediated translation and HAV replication. Janus kinase (JAK) inhibitors inhibit La protein expression, HAV IRES activity, and HAV replication. Based on this review, both DAAs and HTAs may be needed to control effectively HAV infection, and their use should continue to be explored.

No MeSH data available.


Related in: MedlinePlus

Structure of the hepatitis A virus (HAV) and targets of antiviral agents.UTR, untranslated region.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4663202&req=5

f02: Structure of the hepatitis A virus (HAV) and targets of antiviral agents.UTR, untranslated region.

Mentions: HAVcr-1, HAV cellular receptor 1; IRES, internal ribosomal entry-site; UTR, untranslated region.


Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus.

Kanda T, Nakamoto S, Wu S, Nakamura M, Jiang X, Haga Y, Sasaki R, Yokosuka O - J Clin Transl Hepatol (2015)

Structure of the hepatitis A virus (HAV) and targets of antiviral agents.UTR, untranslated region.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4663202&req=5

f02: Structure of the hepatitis A virus (HAV) and targets of antiviral agents.UTR, untranslated region.
Mentions: HAVcr-1, HAV cellular receptor 1; IRES, internal ribosomal entry-site; UTR, untranslated region.

Bottom Line: There are two forms of antiviral agents against HAV: direct-acting antivirals (DAAs) and host-targeting agents (HTAs).Among the HTAs, amantadine and interferon-lambda 1 (IL-29) inhibit HAV IRES-mediated translation and HAV replication.Janus kinase (JAK) inhibitors inhibit La protein expression, HAV IRES activity, and HAV replication.

View Article: PubMed Central - PubMed

Affiliation: Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Inohana, Chuo-ku, Chiba, Japan.

ABSTRACT
Hepatitis A virus (HAV) infection is a major cause of acute hepatitis and occasionally leads to acute liver failure in both developing and developed countries. Although effective vaccines for HAV are available, the development of new antivirals against HAV may be important for the control of HAV infection in developed countries where no universal vaccination program against HAV exists, such as Japan. There are two forms of antiviral agents against HAV: direct-acting antivirals (DAAs) and host-targeting agents (HTAs). Studies using small interfering ribonucleic acid (siRNA) have suggested that the HAV internal ribosomal entry site (IRES) is an attractive target for the control of HAV replication and infection. Among the HTAs, amantadine and interferon-lambda 1 (IL-29) inhibit HAV IRES-mediated translation and HAV replication. Janus kinase (JAK) inhibitors inhibit La protein expression, HAV IRES activity, and HAV replication. Based on this review, both DAAs and HTAs may be needed to control effectively HAV infection, and their use should continue to be explored.

No MeSH data available.


Related in: MedlinePlus